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Background: Depression and anxiety have been recognized as independent risk factors
for both the development and prognosis of cardiovascular (CV) diseases (CVD). The
Systematic Coronary Risk Evaluation (SCORE) function measures the 10-year risk of
a fatal CVD and is a crucial tool for guiding CV patient management. This study is the
first in Latvia to investigate the association of depression and anxiety with the 10-year
CV mortality risk in a primary care population.
Methods: This cross-sectional study was conducted at 24 primary care facilities. During
a 1-week period in 2015, all consecutive adult patients were invited to complete a
nine-item Patient Health Questionnaire (PHQ-9) and a seven-item Generalized Anxiety
Disorder scale (GAD-7) followed by sociodemographic questionnaire and physical
measurements. The diagnostic Mini International Neuropsychiatric Interview (M.I.N.I.)
was administered by telephone in the period of 2 weeks after the first contact at the
primary care facility. A hierarchical multivariate analysis was performed.
Results: The study population consisted of 1,569 subjects. Depressive symptoms
(PHQ-9≥ 10) were associated with a 1.57 (95% confidence interval (CI): 1.06–2.33) times
higher odds of a very high CV mortality risk (SCORE ≥ 10%), but current anxiety disorder
(M.I.N.I.) reduced the CV mortality risk with an odds ratio of 0.58 (95% CI: 0.38–0.90).
Conclusions: Our findings suggest that individuals with SCORE ≥ 10% should be
screened and treated for depression to potentially delay the development and improve
the prognosis of CVD. Anxiety could possibly have a protective influence on CV
prognosis.
Keywords: depressive symptoms, depression, anxiety, anxiety disorders, 10-year cardiovascular mortality risk,
SCORE, Latvia
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INTRODUCTION
Depression and cardiovascular (CV) diseases (CVD) are the two
most common non-communicable diseases causing disability
and mortality worldwide (1, 2). In Latvia, the mortality rate from
CVD is among the highest in the European Union (EU) and was
responsible for 57% of all deaths in 2015 (3, 4). The standard
premature mortality from CVD is three times higher in Latvia
than in the EU (5).
During the last two decades there is a growing interest in non-
conventional cardiovascular risk factors such as psychosocial
factors. The seminal INTERHEART study, which considered
15,152 myocardial infarction (MI) cases from 52 countries,
showed that nine risk factors were responsible for 90% of the
population attributable risk (PAR) and that psychosocial factors
(including anxiety and depression) alone were responsible for
32.5% of it, suggesting that they were as important as smoking
(PAR, 35.7%) and even more relevant than hypertension (PAR,
17.9%) and diabetes mellitus (PAR, 9.9%) as risk factors for CVD
(6). Depression and anxiety have been established as independent
risk factors for both the onset of and the prognosis of CVD (7, 8),
although the contribution of anxiety as an etiological risk factor
is contradictory (9, 10).
Depressive and anxiety disorders are themost frequent mental
conditions in patients suffering from CVD and are highly
comorbid (11, 12). Between 15 and 20% of CV patients meet the
diagnostic criteria for major depressive disorder (MDD), and an
even larger proportion (40–65%) indicate subsyndromal levels
of depressive symptoms (13, 14). The prevalence of elevated
symptoms of anxiety in CV patients has been reported to be
approximately 30% (12, 14). Data on the relationship between
depression, anxiety and CVD from the Baltic region are limited
and controversial (15–17).
The American Heart Association (AHA) has taken a lead
role in highlighting the importance of depression in CV patients
by recommending routine screening of all cardiac patients in
2008 (18, 19). However, a recent systematic review by Thombs
et al. (20) found no evidence that this strategy improves
depression or cardiac outcomes (20). Furthermore, in patients
with already diagnosed coronary artery disease (CAD), mental
health interventions for MDD showed moderate efficacy for
reducing cardiac events, but remained controversial in the ability
to reduce total mortality (7, 21). This finding underscores the
importance of primary prevention of CVD and the need to
identify the target population who would most benefit from
depression and anxiety screening.
The Systematic Coronary Risk Evaluation (SCORE) function
measures the 10-year risk of a fatal CVD. The SCORE charts
have been elaborated to rapidly calculate CV mortality risk
with sufficient accuracy in both high- and low-risk European
populations. Since 1994, the SCORE has been widely advocated
by the joint recommendations from the European Association
of Preventive Cardiology, European Society of Cardiology,
European Atherosclerosis Society and European Society of
Hypertension (7, 22). There is also an electronic version of the
SCORE risk charts that is even easier to use in daily clinical
practice (23).
This project aimed to be the first study to examine the
association of anxiety and depression with the 10-year CV
mortality risk in a primary care population of Latvia. This
research addresses a relevant gap in the body of knowledge
concerning Latvian, Baltic and East European populations. The
study findings have implications for medical education, policy,
and program development in these countries.
MATERIALS AND METHODS
The current research was performed in 2015 as a part of
the National Research Program BIOMEDICINE (2014–2017) to
estimate the frequency of most common psychiatric disorders in
primary care population of Latvia. The study approached patients
of 24 primary care facilities across the country (8 in rural and 16
in urban regions). This research was carried out in the two most
widely spoken languages in Latvia (Latvian and Russian).
Ethics
This study was authorized by the Ethics Committee of the
Riga Stradins University, Riga, Latvia (No. 8/18.06.2015.). All
subjects were included in the study only after signing written
informed consent. The research was conducted accordingly with
the Declaration of Helsinki and its subsequent amendments.
Subjects and Procedures
The inclusion criteria were as follows: all consecutive treatment-
seeking patients attending primary care facility, persons who
were 18 years of age or older, and subjects who had provided
their informed consent. The exclusion criteria were as follows:
persons who declined to be enrolled in this research project,
persons who were younger than 18 years of age, and persons who
presented with an urgent health complaints requiring immediate
intervention.
During 1 week period in 2015, all consecutive adult
persons who corresponded to the inclusion criteria were
approached to complete the Patient Health Questionnaire
(PHQ-9) for screening of depressive symptoms and the
Generalized Anxiety Disorder questionnaire (GAD-7) for
screening of anxiety symptoms in Latvian or Russian (language as
preferred by participant), followed by a structured interview on
sociodemographic characteristics and measurements of weight,
height, waist circumference, total cholesterol, and blood pressure.
The diagnostic Mini International Neuropsychiatric Interview
(M.I.N.I.) was administered by telephone in the period of 2 weeks
after the first contact at the primary care facility by specially
trained interviewers (psychiatrists). SCORE was calculated for
each individual patient using the electronic version of the
high risk chart developed and supported by the European
Society of Cardiology (23). Information about the prescription
of cardiovascular and psychotropic medications from the last 3
months were acquired using medical records.
Assessment Tools and Measures
The Patient Health Questionnaire-9 is a nine-item self-reported
depression screening tool based on the diagnostic criteria for
MDD according to the Diagnostic and Statistical Manual of
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Mental Disorders, Fourth Edition (DSM-IV) (24). Recent meta-
analysis by Meader and colleagues that aimed to define the most
effective tool for detection of MDD in persons with chronic
somatic diseases showed that among other widely used screening
instruments the PHQ-9 revealed good diagnostic accuracy. A
score of 10 or higher on the PHQ-9 had a sensitivity of 84% and
a specificity of 88% for detecting MDD (25). Both Latvian and
Russian versions of the PHQ-9 for Latvia were validated as part of
the National Research Project BIOMEDICINE (2014–2017) (26).
The 7-item Generalized Anxiety Disorder scale is a self-rating
screening tool for anxiety symptoms (27). The GAD-7 has been
established as a reliable tool for detection of most common
anxiety disorders. A cut-off score of 10 points and higher has
a sensitivity of 89% and a specificity of 82% for generalized
anxiety disorder (GAD). It is moderately good at screening panic
disorder (PD) (sensitivity-74%, specificity-81%), social anxiety
disorder (sensitivity-72%, specificity-80%), and post-traumatic
stress disorder (PTSD) (sensitivity-66%, specificity-81%) (28).
The M.I.N.I. is a structured diagnostic interview for most
common mental disorders in accordance with the DSM-IV and
the 10th version of the International Classification of Diseases
(29). The M.I.N.I. has been previously translated for use in
Latvian and Russian languages by authorship holders. The
M.I.N.I. authorship holder prof. David Sheehan provided written
permission to use this scale in our study.
The SCORE system measures the 10-year risk of a fatal CV
event (e.g., stroke, myocardial infarction or aneurysm of the
aorta). The SCORE risk assessment is derived using data from
12 European cohort studies with 205,178 participants covering
a wide geographic spread of countries at different levels of CV
risk. The SCORE charts have been elaborated to calculate risk
in both high- and low-risk European populations. The reported
predictive values representing areas under receiver operating
characteristic curves for SCORE have ranged from 0.71 to 0.84
(22). Total CV risk estimation using SCORE is a crucial tool
for supporting clinicians during the optimization of individual
CV risk reduction in apparently healthy individuals. This risk
estimation is based on the following risk factors: gender, age,
smoking, systolic blood pressure, and total cholesterol. The
threshold for very high risk is defined as a calculated SCORE ≥
10%, and it was used as a cut-off score in our study (7, 23).
The sociodemographic questionnaire included questions
about demographics (age, sex, ethnicity, marital status,
education), CV risk factors, history of CVD, diabetes mellitus and
psychiatric disorders, use of CV and psychotropic medications.
The section on CV risk factors included questions about family
history of premature CVD in first-degree relatives (<55 years
in men and <65 years in women), physical activity (number of
moderate exercise sessions of at least 30min per week), smoking
habits (smoking status, number of cigarettes), alcohol use, and
consumption of fresh vegetables, fruits and fish.
Statistical Analysis
Statistical analysis was performed using Statistical Package for the
Social Sciences (SPSS) version 20.0 (IBM SPSS Corp.). Statistical
significance was considered as p < 0.05. Differences of the study
sample between comparative SCORE groups were detected using
Chi-Square test or Fisher’s exact test.
To examine associations of depression and anxiety with the
SCORE function, we conducted an univariate and stepwise
multivariate analysis (using binary logistic regression) according
to the conceptual hierarchical framework model (30), in which
possible confounding variables were distributed into 3 groups:
proximal (positive family history, number of cigarettes, diabetes,
use of antihypertensive, cholesterol lowering medications),
intermediate (body mass index/waist circumference, depression
and/or anxiety, sedentary lifestyle, consumption of fresh
vegetables and fruits, consumption of fish, alcohol use) and
distal factors (education, employment status, marital status, place
of residence). Factors that were used in the calculation of the
SCORE function (gender, age, blood pressure, total cholesterol,
smoking status) were excluded from the list of independent
variables in the regression analysis.
As current depressive episode according to the M.I.N.I.
and anxiety symptoms detected by the GAD-7 did not show
statistically significant results in the univariate analysis, these
measures were not included in the final regression model. To
gain more statistical power, we combined all anxiety disorders
according to the M.I.N.I. into one current anxiety variable for
the final analysis, including GAD, PD, PTSD, and agoraphobia.
Previous research has demonstrated that these anxiety disorders
contribute to the risk of developing CVD and a worse prognosis
of CVD (7, 31).
RESULTS
From 1,756 approached subjects 152 declined to participate in
this study. The mean response rate was 91.3%, it varied between
86.3 and 93.7% across 24 primary care facilities all over the
country. Those who declined did not significantly differ in the
basic sociodemographic characteristics from the study sample. In
total, 1,604 patients were approached to complete the PHQ-9 and
the GAD-7 questionnaires, which were completed by 1,585 of
participants. Among those who completed both questionnaires,
the SCORE measure was calculated for 1,569 subjects (69.0%
women), who were included in the final analysis. Of the eligible
study subjects, 23.4% (n = 367) showed a very high 10-year
CV mortality risk according to the SCORE (≥10%). Clinical
symptoms of depression (PHQ-9 ≥ 10) were present in 15.0%
(n = 233) of individuals. According to the M.I.N.I., 10.2%
(n = 148) had current and 28.1% (n = 410) had a lifetime
depressive episode. Clinically relevant anxiety symptoms (GAD-
7 ≥ 10) were detected in 10.1% (n = 156) of individuals.
According to the M.I.N.I., 15.9% (n= 232) had a current anxiety
disorder. A complete description of the sample is shown in
Table 1.
In the final multivariate analysis model (Table 2), a very
high risk of CV mortality was significantly associated with three
proximal factors: presence of diabetes, use of antihypertensive
and cholesterol lowering medicines. Among distal factors, three
variables increased the risk of CV mortality: lower education
level, inactive economic status or unemployment, and urban
place of residence.
The only intermediate factors that remained significantly
associated with a SCORE ≥ 10% after adjustment for socio-
economic and traditional CV risk factors were depression
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TABLE 1 | Description of the study sample.
Independent variable SCORE ≥ 10% SCORE ≤ 9% p Total
n % n % n %
PROXIMAL FACTORS
Positive family history of previous cardiovascular disease
Don‘ t know 24 6.6 40 3.3 0.01 64 4.1
Yes 124 33.9 467 39.1 591 37.9
No 218 59.6 688 57.6 906 58.0
Diabetes mellitus
Yes 75 20.4 65 5.6 <0.001 140 9.1
No 292 79.6 1,102 94.4 1,394 90.9
Antihypertensives
Yes 290 79.0 466 38.8 <0.001 756 48.2
No 77 21.0 736 61.2 813 51.8
Cholesterol lowering medicines
Yes 124 33.8 111 9.2 <0.001 235 15.0
No 243 66.2 1,091 90.8 1,334 85.0
Antidepressants
Yes 12 3.3 35 2.9 0.73 47 3.0
No 355 96.7 1167 97.1 1522 97.0
INTERMEDIATE FACTORS
Body mass index, kg/m2
<18.50 (underweight) 2 0.5 25 2.1 0.009 27 1.7
18.50–24.99 (normal) 143 24.1 391 30.5 534 34.1
25.00–29.99 (overweight) 132 36.2 419 34.9 551 35.2
30.00+ (obese) 88 39.2 366 32.6 454 29.0
Waist circumference, cm
Increased (88+ females; 102+ males) 209 57.3 557 46.6 <0.001 766 49.1
Normal (≤88 females; ≤102 males) 156 42.7 639 53.4 795 50.9
Sedentary lifestyle (30min. of moderate physical activity)
Unable to perform 62 17.0 107 9.0 <0.001 169 10.9
1 time a week or less 141 38.7 540 45.4 681 43.8
2–3 times a week 44 12.1 164 13.8 208 13.4
4–6 times a week 35 9.6 139 11.7 174 11.2
Every day 82 22.5 240 20.2 322 20.7
Depression (PHQ-9)
Is present 73 20.2 160 13.4 0.002 233 15.0
Not present 289 79.8 1030 86.6 1319 85.0
Current depression (M.I.N.I.)
Yes 42 12.6 106 9.4 0.09 148 10.2
No 292 87.4 1,017 90.6 1,309 89.8
Lifetime depression (M.I.N.I.)
Yes 97 29.0 313 27.9 0.68 410 28.1
No 237 71.0 810 72.1 1,047 71.9
Anxiety (M.I.N.I., any anxiety disorder)
Is present 43 12.9 189 16.8 0.08 232 15.9
Not present 291 87.1 934 83.2 1,225 84.1
Anxiety (GAD-7)
Yes 37 10.2 119 10.0 0.90 156 10.1
No 325 89.8 1,071 90.0 1,396 89.9
Generalized anxiety disorder (M.I.N.I.)
Yes 18 5.4 73 6.5 0.46 91 6.2
No 317 94.6 1,051 93.5 1,368 93.8
(Continued)
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TABLE 1 | Continued
Independent variable SCORE ≥ 10% SCORE ≤ 9% p Total
n % n % n %
Panic disorder (M.I.N.I.)
Yes 1 0.3 10 0.9 0.47 11 0.8
No 334 99.7 1114 99.1 1459 99.2
Alcohol use, episodes of heavy drinking in the last year (5 or more doses of alcohol at once)
Every day or almost every day 4 1.1 10 0.8 <0.001 14 0.9
3–4 times a week 5 1.4 25 2.1 30 1.9
1–2 times a week 22 6.0 112 9.4 134 8.6
More rare 78 21.3 389 32.6 467 29.9
Never during the past year 257 70.2 659 55.1 916 58.7
Consumption of fresh vegetables and fruits
Yes 258 70.5 896 75.0 0.09 1154 73.9
No 108 29.5 299 25.0 407 26.1
Consumption of fish
Yes 151 41.3 455 38.1 0.28 606 38.8
No 215 58.7 740 61.9 955 61.2
DISTAL FACTORS
Education
9-years basic and unfinished basic
education
83 22.7 131 11.0 <0.001 214 13.7
General or vocational secondary and
unfinished secondary education
207 56.7 685 57.4 892 57.3
Higher and unfinished higher
education
75 20.5 377 31.6 452 29.0
Employment status
Economically inactive 260 71.0 400 33.5 <0.001 660 42.3
Unemployed 16 4.4 72 6.0 88 5.6
Employed 90 24.6 722 60.5 812 52.1
Marital status
Single 19 5.2 134 11.2 <0.001 153 9.8
Live separately, divorced, widowed 144 39.3 310 26.0 454 29.1
Married, cohabiting 203 55.5 750 62.8 953 61.1
Place of residence
Riga 123 33.5 189 15.7 <0.001 312 19.9
Other city 160 43.6 588 48.9 748 47.7
Rural 84 22.9 425 35.4 509 32.4
SCORE, Systematic Coronary Risk Evaluation, estimates the 10-year risk of a first fatal atherosclerotic event; (22) PHQ-9, a nine-item Patient Health Questionnaire; M.I.N.I., the diagnostic
Mini International Neuropsychiatric Interview; GAD-7, a seven-item Generalized Anxiety Disorder scale.
(according to the PHQ-9) and anxiety (according to theM.I.N.I.).
Subjects with clinical symptoms of depression had a 1.57
(p = 0.03) times higher odds of very high CV risk. Interestingly,
current anxiety disorder showed a preventive effect on CV
mortality. Subjects with diagnosed anxiety disorder had a 0.58
lower odds (p= 0.02) of having a SCORE ≥ 10%.
DISCUSSION
This is the first study in Latvia to explore the relationship
between depression, anxiety and the 10-year risk of a first
fatal atherosclerotic event in primary care population based
on the SCORE system. The most relevant findings were that
patients with clinical symptoms of depression (PHQ-9 ≥ 10)
demonstrated a 1.57 times higher odds of a very high 10-year
CV risk as measured by the SCORE function, but current anxiety
disorder (M.I.N.I.) reduced the risk of CV mortality with an OR
of 0.58. These findings remained statistically significant even after
adjusting for multiple socio-demographic and traditional CV risk
factors.
A global overview of the literature from approximately 50
prognostic studies on the link between depression and CVD from
the last 25 years concluded that clinically relevant depressive
symptoms are associated with a 1.6 to 2.2-fold higher risk of
adverse outcomes (31, 32); however, prior studies in the Baltic
nations have been contradictory. A prospective cohort study of
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TABLE 2 | Factors associated with a very high risk of cardiovascular mortality in univariate and hierarchical multivariate analysesa.
Independent variable ORb 95% CI p-Value aOR1c 95% CI p-Value aOR2d 95% CI p-Value aOR3e 95% CI p-Value
PROXIMAL FACTORS
Positive family history of early cardiovascular disease
Don‘t know vs. no 1.89 1.12–3.21 0.02 1.81 1.01–3.24 0.045 2.09 1.08–4.06 0.03 1.23 0.62–2.46 0.55
Yes vs. no 0.84 0.65–1.08 0.17 0.66 0.50–0.87 0.003 0.69 0.51–0.93 0.01 0.88 0.64–1.20 0.42
Diabetes mellitus
Yes vs. no 4.36 3.05–6.22 < 0.001 2.45 1.66–3.62 < 0.001 2.88 1.84–4.52 < 0.001 2.52 1.63–3.89 < 0.001
Antihypertensive medications
Yes vs. no 5.95 4.51–7.85 < 0.001 4.26 3.17–5.74 < 0.001 5.13 3.59–7.32 < 0.001 3.22 2.29–4.53 < 0.001
Cholesterol lowering medications
Yes vs. no 5.02 3.75–6.71 < 0.001 2.55 1.86–3.51 < 0.001 2.50 1.77–3.52 < 0.001 2.07 1.44–2.95 < 0.001
Antidepressants
Yes vs. no 1.13 0.58–2.20 0.73 1.05 0.50–2.21 0.90
INTERMEDIATE FACTORS
Body mass index, kg/m2
<18.50 (underweight) vs.
18.50–24.99 (normal)
0.33 0.08–1.43 0.14 0.31 0.04–2.48 0.27
25.00–29.99 (overweight) vs.
18.50–24.99 (normal)
1.29 0.97–1.78 0.08 0.95 0.65–1.40 0.80
30,00+ (obese) vs. 18.50–24.99
(normal)
1.52 1.13–2.06 0.006 0.76 0.46–1.25 0.28
Waist circumference, cm
Increased (88+ females; 102+ males)
vs. Normal (≤88 females; ≤102
males)
1.54 1.21–1.98 < 0.001 0.71 0.48–1.07 0.10
Sedentary lifestyle–30min of moderate physical activity
4–6 times a week vs. Every day 0.74 0.47–1.15 0.18 0.93 0.55–1.56 0.78
2–3 times a week vs. Every day 0.79 0.52–1.19 0.26 0.88 0.54–1.44 0.61
1 time a week or less vs. Every day 0.76 0.56–1.04 0.09 0.70 0.48–1.02 0.06
Unable to perform vs. Every day 1.70 1.14–2.53 0.01 1.04 0.64–1.70 0.87
Depression (PHQ-9)
Is present vs. not present 1.63 1.18–2.21 0.002 1.65 1.12–2.42 0.01 1.57 1.06–2.33 0.03
Anxiety (M.I.N.I., any anxiety)
Is present vs. not present 0.73 0.51–1.04 0.08 0.58 0.38–0.89 0.01 0.58 0.38–0.90 0.02
Alcohol consumption, episodes of
heavy drinking in the last year (5 or
more doses of alcohol at once)
Every day or almost every day vs.
Never during the past year
1.03 0.32–3.30 0.97 1.24 0.30–5.14 0.76
3–4 times a week vs. Never during
the past year
0.51 0.19–1.35 0.18 0.68 0.21–2.18 0.51
1–2 times a week vs. Never during
the past year
0.50 0.31–0.81 0.005 0.94 0.51–1.73 0.84
More rare vs. Never during the past
year
0.51 0.39–0.68 < 0.001 0.78 0.55–1.10 0.15
Consumption of fresh vegetables and fruits (every day)
No vs. yes 1.25 0.97–1.63 0.09 1.12 0.81–1.54 0.50
Consumption of fish (≥2 times a
week)
No vs. yes 0.88 0.69–1.11 0.28 0.96 0.71–1.28 0.77
DISTAL FACTORS
Education
9-years basic and unfinished basic
education vs. Higher and unfinished
higher education
3.19 2.20–4.61 < 0.001 2.25 1.39–3.65 0.001
(Continued)
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TABLE 2 | Continued
Independent variable ORb 95% CI p-Value aOR1c 95% CI p-Value aOR2d 95% CI p-Value aOR3e 95% CI p-Value
General or vocational secondary and
unfinished secondary education vs.
Higher and unfinished higher
education
1.52 1.13–2.04 0.005 1.29 0.90–1.84 0.17
Employment status
Economically inactive vs. Employed 5.21 3.98–6.82 < 0.001 2.87 2.07–3.98 < 0.001
Unemployed vs. Employed 1.78 0.99–3.20 0.052 2.05 1.05–4.01 0.04
Marital status
Single vs. Married, cohabiting 0.52 0.32–0.87 0.01 0.65 0.35–1.23 0.19
Live separately, divorced, widowed
vs. Married, cohabiting
1.72 1.34–2.21 < 0.001 0.94 0.69–1.29 0.71
Place of residence
Riga vs. rural 3.29 2.38–4.56 < 0.001 4.00 2.62–6.10 < 0.001
Other city vs. rural 1.38 1.03–1.84 0.03 1.55 1.08–2.22 0.02
OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; PHQ-9, a nine-item Patient Health Questionnaire; M.I.N.I., the diagnostic Mini International Neuropsychiatric Interview.
aCells in the table are left empty intentionally due to the stepwise multivariate analysis according to conceptual hierarchical framework model (see Methods part for more detailed
information). bOR, crude odds ratio. caOR1, adjusted odds ratio in first model, proximal factors adjusted. daOR2, adjusted odds ratio in second model, proximal, and intermediate
factors adjusted. eaOR3, adjusted odds ratio in third model, proximal, intermediate, and distal factors adjusted.
primary care population (n = 1,115) in Lithuania examined the
association of the metabolic syndrome, current major depressive
episode, lifetime major depressive episode, and GAD with 10-
year CV mortality (33). Butnoriene et al. (33) found that lifetime
major depressive episode was associated with an elevated risk
of CV mortality in women (HR = 1.86; p = 0.019) adjusted
for conventional CV risk factors. In men, neither current MDE
nor lifetime MDE were associated with mortality. Another study
from Lithuania by Burokiene et al. (15) showed a more modest
but statistically significant association of CV morbidity and
clinically relevant depressive symptoms (OR = 1.18; p = 0.001).
Surprisingly, a cross-sectional study involving 1,094 patients
from 23 family practices across Estonia did not indicate higher
co-morbidity of CVD in depressed patients when compared to
non-depressed patients (16). Our findings about the association
of depression with CV mortality are in line with prior studies
identifying depression as an independent risk factor for CV
morbidity and mortality.
Although many studies have examined the association
of depression with separate traditional CV risk factors,
including arterial hypertension, hypercholesterolemia, diabetes
and obesity, we found only one publication that used the
SCORE system (34). Koponen et al. (34) reported that clinically
relevant depressive symptoms were associated with a 2.9-fold
higher (95% CI 1.4–5.7) 10-year CV mortality risk in men and
a 1.4-fold higher (95% CI 1.1–4.2) risk in women using the
SCORE function. Despite similar objectives, there were several
significant differences in the methodology of this study. In the
study by Koponen et al. (34) a “high/very high” risk for CV
mortality was defined as a SCORE ≥ 3%. We chose a SCORE
≥ 10% as a threshold for very high risk of CV mortality in
accordance with the European Guidelines on cardiovascular
disease prevention in clinical practice (2016) (7). We also used
additional confounding factors such as place of residence and
anxiety, which appeared to have a significant impact on the
SCORE results.
In contrast to depression, the relationship between anxiety
and CVD is less clear. Meta-analysis by Roest et al. (35)
summarizing 20 studies with 249,846 participants found that
anxious persons were at an increased risk for incident CAD
(HR = 1.26; p < 0.0001) and CV mortality (HR = 1.48;
p = 0.003), independent of sociodemographic characteristics,
traditional and lifestyle CV risk factors (35). However, the meta-
analytic assessment on the link between anxiety and CAD was
not controlled for depression, which is very frequent comorbid
condition with anxiety. Since the publication of that review in
2010, more recent studies have suggested that anxiety may act as
a protective factor in certain instances (9, 10). The most recent
meta-analysis (2016) also included studies focusing on stroke
and peripheral vascular disease, summarizing 37 studies with
1,565,699 participants (36). Batelaan and colleagues found that
clinically relevant anxiety symptoms were associated with a 1.52
times higher risk of incident CV morbidity (95% CI 1.36–1.71).
Although the data on the prognostic influence of anxiety are
complex and even controversial, most publications support the
association of anxiety with CVmortality, but they do so to a lesser
extent compared with depression. In addition, a few studies have
been performed in the Baltic region, but none have examined the
association of anxiety with the SCORE function. Butnoriene et al.
(33) showed that current GAD predicted greater CV mortality in
women (HR = 1.86–1.99; p ≤ 0.025), but not in men. A small
study (n = 64) from Estonia also reported differences between
young male and female post-MI patients, indicating that females
suffered a higher level of cognitive worry and were less able to
relax in the prodromal period of MI (37).
One of the most unexpected findings of our study was that
current anxiety disorder (M.I.N.I.) was associated with a reduced
CV mortality risk, suggesting a possible protective influence.
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This result is in agreement with the findings of Meyer et al. (9),
which showed that elevated symptoms of anxiety were associated
with beneficial effects on survival in individuals with stable CV
conditions (HR = 0.70; p = 0.031) comparing to individuals
after acute MI with reduced systolic left ventricular function
(HR = 1.32; p = 0.011) (9). Therefore, it has been hypothesized
that prognostic influence of anxiety might be modulated through
CVD severity (degree of left ventricular dysfunction).
The use of a structured diagnostic interview for the detection
of anxiety disorders, a nationally representative primary care
convenience sample including persons with a wide range of ages,
and a hierarchical multivariate analysis including control for
conventional CV, socioeconomic risk factors, anxiety and place
of residence are important strengths of this study.
There are several limitations to the results of current study.
First, because of the cross-sectional setting of this study, we could
not draw definite conclusions about the causality of the identified
relationships between clinically relevant depressive symptoms or
anxiety disorders and cardiovascular mortality risk. Second, the
PHQ-9 with a cut-off score of 10 points and higher has been
accepted as a reliable instrument for detection ofMDD in chronic
physical diseases (25). However, the PHQ-9 is a screening tool
and not a diagnostic criterion for MDD, which can result in
false positive cases. Third, we combined all anxiety disorders
according to the M.I.N.I., including GAD, PD, agoraphobia,
and PTSD, in the current anxiety variable of the final analysis
to gain more statistical power. Although these diagnoses share
the common basic symptoms of anxiety and neurobiological
mechanisms (38, 39), we were unable to clarify whether our
findings were attributable to all included anxiety disorders.
CONCLUSIONS
We found a statistically significant association between
depression (PHQ-9 ≥ 10) and a very high risk of CV mortality.
In contrast to our expectations, current anxiety disorder
(M.I.N.I.) was found to be negatively associated with CV
mortality risk (SCORE ≥ 10%), which suggests that anxiety
could potentially have a protective influence on CV prognosis.
The findings of this study suggest that individuals with the
SCORE ≥ 10% could benefit from screening and treatment of
depression to potentially delay the development and improve the
prognosis of CVD. Further research is needed to investigate the
influence of anxiety on CV mortality risk in Latvian population.
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